Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

ECMO studied in 761 severe COVID-19 patients: does it help?

NCT ID NCT04397588

Knowledge-focused Sponsor: Rennes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether ECMO, a machine that does the work of the heart and lungs, helps people with severe COVID-19 who have lung failure or heart failure. Researchers tracked 761 patients across France to see how many survived and how quickly they recovered. The goal was to understand if ECMO is a useful option for the sickest COVID-19 patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Extracorporeal membrane oxygenation (ECMO)
What this could lead to
If successful, this could clarify whether ECMO improves survival in the sickest COVID-19 patients, guiding future treatment protocols.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove ECMO is better than other treatments. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

761 people

The number who actually took part.

Started

Apr 2020

Finished

May 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Critically ill COVID-19 patients with ARDS or/and acute refractory heart failure

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All COVID-19 patients, adults or children, * Tested positive by RT-PCR for SARS-CoV2 (nasopharyngeal swabs, sputum, endotracheal aspiration, bronchoalveolar lavage or stool sample) and / or with a diagnosis made on chest CT findings, * Supported by venovenous or venoarterial ECMO Exclusion Criteria: * Temporary legally protected Adults over a set period or waiting for protection supervision, guardianship * Patients or proxies who express their opposition to study participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute refractory heart failure related to SARS-CoV 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19 heart failure myocarditis severe acute respiratory syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute refractory heart failure related to SARS-CoV 2 ARDS related to severe acute respiratory syndrome-coronavirus (SARS-CoV) 2

Contacts and locations

Locations

  • APHM la Timone- Marseille University Hospital

    Marseille, 13005, France

  • APHP Bichat - Paris University Hospital

    Paris, 75018, France

  • APHP Henri Mondor Paris University Hospital

    Créteil, 94000, France

  • APHP Hopital Européen Georges Pompidou - Paris University Hospital

    Paris, 75015, France

  • APHP Kremli Bicetre Paris University Hospital

    Le Kremlin-Bicêtre, 94275, France

  • APHP La Pitié Salpêtrière Paris University Hospital

    Paris, 75651, France

  • APHP necker Paris University Hospital

    Paris, 75015, France

  • Ambroise Paré Hospital

    Neuilly-sur-Seine, 92200, France

  • Angers University Hospital

    Angers, 49933, France

  • Besançon Hospital

    Besançon, 25030, France

  • Bordeaux University Hospital

    Pessac, 33604, France

  • Brest university Hospital

    Brest, 29200, France

  • Bretagne Atlantique Hospital

    Vannes, 56000, France

  • Caen University Hospital

    Caen, 14033, France

  • Clairval Hospital

    Marseille, 13009, France

  • Clermont ferrand University hospital

    Clermont-Ferrand, 63003, France

  • Clinique de la Sauvegarde

    Lyon, 69337, France

  • Dijon University Hospital

    Dijon, 21079, France

  • Emile Muller Hospital

    Mulhouse, 68051, France

  • Grenoble University Hospital

    La Tronche, 38700, France

  • Institut Mutualiste Montsouris

    Paris, 75014, France

  • La Réunion University Hospital

    Saint-Denis, 97400, France

  • Lens Hospital

    Lens, 62307, France

  • Lille University Hospital

    Lille, 59000, France

  • Limoges University Hospital

    Limoges, 87042, France

  • Lyon University Hospital

    Lyon, 69500, France

  • Marie Lannelongue Hospital

    Le Plessis-Robinson, 92350, France

  • Marseille Européen Hospital

    Marseille, 13003, France

  • Metz University Hospital

    Metz, 45000, France

  • Montpellier University Hospital

    Montpellier, 34090, France

  • Nancy University Hospital

    Nancy, 54511, France

  • Nantes University Hospital

    Nantes, 44000, France

  • Nimes University Hospital

    Nîmes, 30029, France

  • Poitiers University hospital

    Poitiers, 86000, France

  • Reims University hospital

    Reims, 51092, France

  • Rennes University hospital

    Rennes, 35000, France

  • Rouen University Hospital

    Rouen, 76031, France

  • Saint Etienne University Hospital

    Saint-Etienne, 42000, France

  • Saint Nazaire Hospital

    Saint-Nazaire, 44606, France

  • Saint brieuc Hospital

    Saint-Brieuc, 22027, France

  • Strasbourg University Hospital

    Strasbourg, 67091, France

  • Toulouse University Hospital - Rangueil Hospital

    Toulouse, 31000, France

  • Tours University Hospital

    Tours, 37044, France

  • Vendée Hospital

    La Roche-sur-Yon, 85000, France